NEW YORK ( TheStreet) -- CHANGE IN RATINGSAutodesk ( ADSK) downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating. Adtran ( ADTN) upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter. Cummins ( CMI) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing. Concur ( CNQR) downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target. Devon Energy ( DVN) downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims. Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook. Exelon ( EXC) upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend. FirstMerit ( FMER) upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target. Health Net ( HNT) upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving. Juniper ( JNPR) upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending. Linear Technology ( LLTC) upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation. Universal Display ( PANL) downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility. Parker Hannifin ( PH) upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target. Perrigo ( PRGO) downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals. PSS World Medical ( PSSI) downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.